UP!

GMED $51.2

GMED target price
51.20
0
0
Globus Medical, Inc.
Type
Public
Traded as NYSE: GMED
S&P 400 Component
Industry Medical Technology
Founded 2003
Headquarters Audubon, Pennsylvania
Key people
David C. Paul
(Chairman/Co-Founder)
David M. Demski (CEO)
Anthony L Williams
(President)
A Brett Murphy
(President:Commercial Ops)
Products Medical Devices
Revenue $544.75 Million (2015)
Number of employees
1,200 (2016)
Website http://www.globusmedical.com/

Globus Medical, Inc., based in Audubon, PA, is a medical device company focused on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. Globus Medical is a publicly traded company and is listed on the NYSE under the symbol GMED.

The company's products are classified into two categories: Innovative Fusion and Disruptive Technologies. The Innovative Fusion products are uses in cervical, thoracolumbar, sacral, and interbody, corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions. Globus Medical to date has developed a portfolio of spine products, releasing more than 150 products.

January 8, 2014 Globus Medical, Inc announced that it has acquired Excelsius Surgical.The Excelsius system is designed to integrate intra-operative digital imaging with a robotic surgery device to hold patients in place during surgeries "with sub-millimeter accuracy"

October 23, 2014 Globus Medical acquired allograft tissue processor Transplant Technologies of Texas, Ltd. (TTOT). TTOT is a provider of human tissue products including bone allografts, biomaterials, and soft tissue products for spine, orthopedics, sports medicine, dental, and wound care markets.

February 26, 2015, Globus Medical acquired Branch Medical Group, a third party manufacturer of high precision medical devices.

July 26, 2016 ,Globus Medical acquired Alphatec Holdings, Inc international operations and distribution channel for a purchase price of $80 million. As part of the transaction, Globus has also agreed to provide Alphatec a five-year senior secured credit facility of up to $30 million.

Globus Medical ranked #27 in Forbes Lists of America's Best Small Companies (2013)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-11-02 Future report Set alerts
Q2 2022 2022-08-04 0.00 0.00
Q1 2022 2022-05-10 0.42 0.42
Q4 2021 2022-02-17 0.49 0.49
Q3 2021 2021-11-04 0.00 0.00
Q2 2021 2021-08-04 0.56 0.56
Q1 2021 2021-05-04 0.49 0.49
Q4 2020 2021-02-17 0.58 0.58
Q3 2020 2020-10-28 0.49 0.44
Q2 2020 2020-08-05 0.07 -0.21

Ratings

2016-06-25 Reiterated Rating Piper Jaffray Overweight $29.00
2016-06-25 Reiterated Rating Piper Jaffray Cos. Overweight $29.00
2016-05-27 Initiated Coverage Barclays Equal Weight $26.00
2016-05-27 Initiated Coverage Barclays PLC Equal Weight $26.00
2016-05-26 Downgrade Goldman Sachs Neutral to Sell $21.00
2016-05-26 Downgrade Goldman Sachs Group Inc. Neutral to Sell $21.00
2016-05-16 Downgrade Goldman Sachs Neutral to Sell $26.00 to $21.00
2016-05-04 Reiterated Rating Canaccord Genuity Buy $30.00
2016-05-04 Reiterated Rating Brean Capital Buy
2016-05-04 Reiterated Rating Leerink Swann Buy
2016-05-04 Reiterated Rating Oppenheimer Buy $29.00
2016-05-04 Reiterated Rating Oppenheimer Holdings Inc. Buy $29.00
2016-02-25 Reiterated Rating Canaccord Genuity Buy $30.00
2016-02-25 Reiterated Rating Leerink Swann Outperform $32.00 to $29.00
2016-02-24 Reiterated Rating William Blair Outperform
2016-01-08 Downgrade Bank of America Buy to Underperform $28.00
2016-01-08 Reiterated Rating JMP Securities Buy
2016-01-08 Reiterated Rating Leerink Swann Buy
2016-01-08 Downgrade Bank of America Corp. Buy to Underperform $28.00
2016-01-07 Boost Price Target Leerink Swann Outperform $31.00 to $32.00
2015-11-13 Reiterated Rating Canaccord Genuity Buy
2015-11-13 Initiated Coverage Oppenheimer Buy
2015-11-04 Reiterated Rating Brean Capital Buy
2015-11-04 Boost Price Target Leerink Swann Outperform $28.00 to $29.00
2015-11-04 Reiterated Rating Canaccord Genuity Buy $35.00
2015-10-19 Lower Price Target Leerink Swann Outperform $32.00 to $28.00
2015-10-15 Reiterated Rating Morgan Stanley Overweight $32.00
2015-09-28 Initiated Coverage Morgan Stanley Overweight $32.00
2015-09-14 Initiated Coverage Morgan Stanley Overweight $32.00
2015-08-27 Lower Price Target Goldman Sachs $27.00 to $26.00
2015-08-03 Boost Price Target Leerink Swann Outperform $30.00 to $32.00
2015-07-27 Reiterated Rating Brean Capital Buy $33.00
2015-05-20 Set Price Target Canaccord Genuity Buy $31.00
2015-05-06 Reiterated Rating Canaccord Genuity Buy $31.00
2015-05-06 Reiterated Rating Oppenheimer Outperform $28.00
2015-05-06 Boost Price Target Brean Capital Buy $30.00 to $33.00
2015-04-26 Reiterated Rating Canaccord Genuity Buy $31.00
2015-04-23 Set Price Target Brean Capital Buy $30.00
2015-04-14 Initiated Coverage Wells Fargo & Co. Outperform
2015-04-14 Initiated Coverage Wells Fargo Outperform
2015-03-20 Set Price Target Canaccord Genuity Buy $31.00
2015-03-17 Set Price Target Oppenheimer Buy $28.00
2015-03-02 Boost Price Target WallachBeth Capital Buy $26.00 to $30.00
2015-02-27 Boost Price Target Leerink Swann Outperform $28.00 to $29.00
2015-02-26 Boost Price Target Brean Capital Buy $28.00 to $30.00
2015-02-26 Boost Price Target Canaccord Genuity Buy $28.00 to $31.00
2015-01-26 Set Price Target Canaccord Genuity Buy $28.00
2015-01-07 Boost Price Target JMP Securities Market Outperform $25.00 to $29.00
2015-01-07 Boost Price Target Oppenheimer Outperform $24.00 to $26.00
2015-01-07 Initiated Coverage Piper Jaffray Overweight $28.00
2014-11-11 Initiated Brean Capital Buy $28
2014-11-10 Initiated Coverage Brean Capital Buy $28.00
2014-10-31 Reiterated Rating Canaccord Genuity Buy $24.00 to $28.00
2014-09-11 Boost Price Target Piper Jaffray Top Pick $28.00
2014-09-11 Initiated Coverage JMP Securities Outperform $25.00
2014-08-19 Initiated Coverage Gabelli Buy $30.00
2014-08-06 Upgrade WallachBeth Hold to Buy
2014-08-06 Reiterated Rating Oppenheimer Outperform $28.00 to $24.00
2014-08-06 Upgrade WallachBeth Capital Hold to Buy $27.00 to $24.00
2014-08-06 Lower Price Target Piper Jaffray $28.00 to $26.00
2014-08-06 Lower Price Target Canaccord Genuity Buy $27.00 to $24.00
2014-04-30 Lower Price Target Canaccord Genuity Buy $28.00 to $27.00
2014-02-27 Downgrade WallachBeth Buy to Hold $23 to $27
2014-02-27 Boost Price Target Piper Jaffray $26.00 to $28.00
2014-02-27 Boost Price Target Leerink Swann $26.00 to $28.00
2014-02-27 Downgrade WallachBeth Capital Buy to Hold $23.00 to $27.00
2014-01-22 Boost Price Target Canaccord Genuity Buy $26.00 to $28.00
2013-10-31 Boost Price Target Piper Jaffray Overweight $22.00 to $25.00
2013-10-31 Boost Price Target Canaccord Genuity Buy $24.00 to $26.00
2013-10-14 Downgrade Goldman Sachs Buy to Neutral $19.00 to $18.00
2013-06-24 Reiterated Oppenheimer Outperform $18 to $19
2012-12-14 Reiterated Canaccord Genuity Buy $20 to $22
2012-08-28 Initiated William Blair Outperform
2012-08-28 Initiated Oppenheimer Outperform $18
2012-08-28 Initiated Canaccord Genuity Buy $20
2016-06-25 Reiterated Rating Piper Jaffray Overweight $29.00
2016-06-25 Reiterated Rating Piper Jaffray Cos. Overweight $29.00
2016-05-27 Initiated Coverage Barclays Equal Weight $26.00
2016-05-27 Initiated Coverage Barclays PLC Equal Weight $26.00
2016-05-26 Downgrade Goldman Sachs Neutral to Sell $21.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
GOLDMAN SACHS GROUP INC 8.10%  (7643526) AHS / AMBR / ARMK / ARX / BNFT / CIE / EBIX / EDMC / EIGI / ENLK / ESNT / GFF / GMED / GS / H / HABT / KMI / LACO / LLNW / MGI / MRC / PNRG / TIPT / TTOO / ZINC / ZMH /
GOLDMAN SACHS PRIVATE EQUITY PARTNERS 2004 OFFSHORE HOLDINGS, L.P. 8.10%  (7643526) GMED /
Davidar David D Vice President, Operations 0.75%  (709775) GMED /
Paul David C Chief Executive Officer 0.65%  (612712) GMED /
Demski David M President and COO 0.16%  (148855) GMED /
WHEELER KURT 0.05%  (44319) GMED / ZGNX /
Murphy A Brett Executive VP, US Sales 0.04%  (35217) GMED /
LIPTAK ROBERT 0.03%  (26159) GMED /
Payne Steven Chief Accounting Officer 0.03%  (23847) GMED /
Williams Anthony L Senior VP of Bus. Devel. & GC 0.02%  (15000) GMED /